Survival prognostic analysis of laparoscopic D2 radical resection for locally advanced gastric cancer: A multicenter cohort study

Table 1 Comparison between 298 locally advanced gastric cancer patients with the time to postoperative recurrence and metastasis ≤ 5 years and > 5 years after laparoscopic assisted D2 radical distal gastrectomy

Clinical pathological factors	Recurrence and metastasis within ≤ 5 years after surgery, n = 255	Recurrence and metastasis after surgery > 5 years, n = 43	Statistical value	P value
Types of recurrence and metastasis	-	-	χ2 = 5.52	0.238
Distant metastasis	21	5	χ2 = 0.53	0.466
Peritoneal metastasis	69	9	χ2 = 0.72	0.398
Local recurrence	37	10	χ2 = 2.12	0.146
Multiple relapses and metastases	52	4	χ2 = 2.9	0.085
Recurrence and metastasis in other parts	76	15	χ2 = 0.45	0.503
Pathological TNM staging	-	-	-	-
Stage II	62	23	χ2 = 15.36	< 0.001
Stage III	193	20
Pathological T-staging	-	-	Z = -1.80	0.07
T2	42	9	χ2 = 0.52	47
T3	95	21	χ2 = 2.08	0.150
T4a	118	13	χ2 = 3.84	0.049
Pathological N-staging	-	-	Z = -3.34	0.001
NO	19	12	χ2 = 16.52	< 0.001
N1	44	5	χ2 = 0.85	0.357
N2	85	18	χ2 = 1.18	0.277
N3	107	8	χ2 = 8.47	0.004

Table 2 Univariate analysis of overall survival rate of locally advanced gastric cancer patients undergoing laparoscopic D2 radical distal gastrectomy

Clinical pathological factors	β value	SE	Wald value	Hazard ratio	95%CI	P value
Sex as female/male	0.03	0.11	0.07	1.03	0.82-1.30	0.788
Age	0.37	0.12	9.58	1.45	1.15-1.84	0.002
Body mass index	-0.25	0.19	1.76	0.78	0.54-1.13	0.19
Scoring for EUSSCG	-	-	1.97	-	-	0.37
1-0	-0.04	0.12	0.09	0.97	0.77-1.21	0.77
≥ 2	0.36	0.28	1.71	1.44	0.84-2.47	0.19
Intraoperative blood transfusion	0.14	0.16	0.82	1.15	0.85-1.56	0.37
Hejing syndrome	0.10	0.13	0.59	1.11	0.85-1.44	0.44
Maximum diameter of the tumor in > 4 cm to ≤ 4 cm	0.49	0.11	20.35	1.64	1.32-2.03	< 0.001
Tumor location	0.00	0.14	0.06	0.97	0.74-1.27	0.81
Remmunm typing	-	-	2.16	-	-	0.34
Type III-IV is more common than Type I-II	0.07	0.12	0.32	1.07	0.85-1.34	0.57
Unknown ratio of type I to type II	-0.23	0.21	1.22	0.80	0.53-1.19	0.27
degree of tumor differentiation	-	-	5.99	-	-	0.05
Low undifferentiated to high medium differentiated	0.31	0.13	5.57	1.37	1.05-1.77	0.02
Unknown high to medium differentiation	0.10	0.23	0.20	0.11	0.71-0.73	0.65
Pathological TNM staging	0.72	0.12	35.29	2.05	1.62-2.59	< 0.001
Pathological T-staging	0.26	0.11	5.69	1.30	1.05-1.61	0.02
Pathological N-staging	-	-	55.20	-	-	< 0.001
N1	0.26	0.21	0.48	1.30	0.85-1.97	0.22
N2	0.52	0.19	7.88	1.68	.17-2.42	0.01
N3	1.13	0.18	37.78	3.08	2.15-4.41	< 0.00
Gastrointestinal reconstruction methods	-	-	4.49	-	-	0.21
Billroth II matches better than Billroth I matches	0.08	0.12	0.41	1.08	0.85-1.37	0.52
Roux-en-Y matches better than Billroth I matches	0.02	0.29	0.00	1.02	0.58-1.82	0.94
Other matches better than Billroth I	0.40	0.19	4.40	1.50	1.03-2.18	0.13
Lymph node dissection	-0.17	0.24	0.46	0.85	0.53-1.36	0.94
Tumor proximal margin	0.00	0.01	0.02	1.00	0.99-1.0	0.88
Distal margin of tumor resection	0.00	0.00	0.02	1.00	0.99-1.0	0.90
Combined organ resection	0.77	0.58	1.78	2.17	0.70-6.75	0.18
Postoperative chemotherapy	-0.59	0.12	24.40	0.56	0.44-0.70	< 0.001
Number of lymph node dissection	0.11	0.17	0.44	1.12	0.80-1.57	0.51
Complications	0.09	0.17	0.26	0.10	0.78-1.52	0.61
Clavien-Dindo ≥ Grade III complications	-0.18	0.50	0.13	0.84	0.31-2.24	0.72

Table 3 Multivariate analysis of overall survival rate of locally advanced gastric cancer patients undergoing laparoscopic D2 radical distal gastrectomy

Clinical pathological factors	β value	SE	Wald value	Hazard ratio	95%CI	P value
Ages of > 65 years to ≤ 65 years	0.24	0.12	3.73	1.27	0.99-1.61	0.053
Maximum diameter of the tumor of > 4 cm to ≤ 4 cm	0.39	0.11	12.19	1.48	1.19-1.84	< 0.001
Degree of tumor differentiation			10.08			0.006
Low undifferentiated to high medium differentiated	0.37	0.14	7.36	1.44	1.11-1.88	0.007
Unknown high to medium differentiation	-0.07	0.23	0.10	0.93	0.60-1.46	0.753
Pathological TNM staging of stage III compared to stage II	0.59	0.12	23.41	1.81	1.42-2.30	< 0.001
Postoperative chemotherapy	-0.56	0.12	20.81	0.57	0.45-0.73	< 0.001